ILP100 is the lead asset and is more specifically L. reuteri expressing human CXCL12 1a. The INN is emilimogene sigulactibac. ILP100 is developed in Oral and Topical formulations.
ILP100-Oral has completed non-clinical development, showing a very favourable safety profile, and in animal models of colitis demonstrated superior efficacy compared to the marketed benchmarks anti-TNFa (Infliximab) and anti-a4b7 (Vedolizumab).
A pre-IND meeting with the FDA was held and the FDA supports evaluation of ILP100-Oral as first line treatment in mild and moderate colitis in cancer patients receiving immune checkpoint inhibitor therapy.